- $938.34m
- $895.51m
- $81.39m
MeiraGTx gains; reports over $200 mln in license revenue
MeiraGTx Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
MeiraGTx Q2 revenue jumps on Reogen license revenue
Brief: Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For Treatment Of Friedreich's Ataxia
Brief: Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For The Treatment Of Friedreich's Ataxia
MeiraGTx Holdings PLC expected to post a loss of 46 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Vera Therapeutics, Vera Therapeutics, Nvidia
U.S. STOCKS ON THE MOVE-Revolution Medicines, Vivani Medical, Nvidia
MeiraGTx rises as Oberland Capital commits up to $400 mln for late-stage gene therapies
U.S. STOCKS ON THE MOVE-Nvidia, Crinetics Pharmaceuticals, Rivian Automotive
MeiraGTx rises as Oberland Capital commits up to $400 mln for late-stage gene therapies
Gene therapy firm MeiraGTx Q1 revenue drops, net loss widens
Brief: MeiraGTx Q1 Revenue USD 293 Thousand Vs. IBES Estimate USD 19.9 Million
U.S. RESEARCH ROUNDUP-Adobe, Chevron, Exxon Mobil
U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings
Gene therapy firm MeiraGTx's 2025 net loss narrows
Brief: MeiraGTx FY EPS USD -1.42
Genetic medicines firm MeiraGTx misses Q3 revenue expectations, net loss widens
Brief: MeiraGTx Q3 EPS USD -0.62